MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 2.3%

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was down 2.3% on Thursday . The company traded as low as $3.23 and last traded at $3.33. Approximately 141,746 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 406,809 shares. The stock had previously closed at $3.41.

MAIA Biotechnology Stock Up 2.7 %

The company has a market cap of $74.69 million, a price-to-earnings ratio of -2.16 and a beta of 0.46.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.13). On average, analysts expect that MAIA Biotechnology, Inc. will post -1.25 earnings per share for the current fiscal year.

Insider Transactions at MAIA Biotechnology

In other MAIA Biotechnology news, Director Ngar Yee Louie acquired 19,665 shares of the company’s stock in a transaction that occurred on Thursday, April 25th. The shares were purchased at an average price of $2.03 per share, with a total value of $39,919.95. Following the completion of the acquisition, the director now directly owns 1,167,189 shares of the company’s stock, valued at approximately $2,369,393.67. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 36.98% of the company’s stock.

Institutional Trading of MAIA Biotechnology

A hedge fund recently bought a new stake in MAIA Biotechnology stock. Virtu Financial LLC acquired a new stake in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 32,487 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned approximately 0.15% of MAIA Biotechnology as of its most recent SEC filing. Institutional investors and hedge funds own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.